- Home
- Providers
- Neurology
- Neurodegenerative Diseases
- Alzheimer’s Disease (AD)
Find Locations
For hours, walk-ins and appointments.Over 6 million people in the US are living with Alzheimer disease (AD)1, and over 80 million adults between 50-70 years whose biggest health fear, other than cancer, is AD2.
We want to help them all.
Our ATN Profile is based on years of research on individual markers that, together, reflect the biological changes consistent with Alzheimer’s disease.
484400
This profile is used to assist in determining the presence or absence of key biological changes that are consistent with Alzheimer's disease pathology
Each of the biomarker tests are orderable individually.
505725
Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a plasma patient sample and computes the ratio of those proteins, providing an indication of amyloid pathology for Alzheimer’s disease
483745
This test detects and quantifies pTau181 proteins in plasma, which has been demonstrated to be predictive in differentiating Alzheimer’s from other dementias
140555
NfL, in the context of Alzheimer’s disease, provides an indication of disease severity by measuring the current level of neurodegeneration
Labcorp is working hard, combining the power of new high precision technology with artificial intelligence to advance diagnostic testing in order to provide clear, objective answers to clinicians, patients, and families.
We are working with blood-based biomarkers, like pTau and NfL, and collaborating with pharmaceutical and diagnostic partners to develop tests that identify, diagnose and monitor patients with AD.